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by Elsevier B.V. This is an open accesAbstract Background and objectives: To determine the effects of intravenous immunoglob-
ulin (IVIg) on the course of late hyporegenerative anemia and the requirement for exchange
transfusions, phototherapy and top-up red blood cell transfusions due to rhesus hemolytic dis-
ease of the newborn (Rh-HDN).
Patients and methods: This is retrospective cohort study of newborns with Rh-HDN who were
treated with or without IVIg. Relevant maternal and neonatal data were obtained and
analyzed. All infants were followed up as outpatients for a period of 2e3 months, and during
the follow ups, complete blood counts (RBCs) were performed every two weeks to diagnose
late hyporegenerative anemia.
Results: Sixty-six infants with Rh-HDN were enrolled in this study (42 in the IVIg group and 24 in
the no-IVIg group). We observed no significant differences between the two groups in terms of
maternal age, number of previous children affected with Rh-HDN, intrauterine transfusions,
gestational age (GA), birth weight (BW), Apgar scores at the 1st or 5th minutes, exchange
transfusions, or days on phototherapy. The serum bilirubin immediately after birth and the
maximum serum bilirubin during the hospital course were significantly higher in the IVIG group
(PZ 0.0035 and PZ 0.0225, respectively). Although there were no statistically significant dif-
ferences, there was a trend toward the late anemia in the IVIg group being diagnosed and
resolved earlier than in the no-IVIg group. Additionally, a greater proportion of the IVIg group
required three or more top-up transfusions compared to the no-IVIg group, but this difference
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74 S. Al-Alaiyan et al.Conclusion: IVIg might have had an effect on the early development of late anemia and might
have shortened the duration of late anemia relative to the infants who did not receive IVIg.
The exchange transfusions and the days on phototherapy were not affected by IVIg.
Copyright ª 2014, King Faisal Specialist Hospital & Research Centre (General Organization),
Saudi Arabia. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The cause of late hyporegenerative anemia is not well un-
derstood; however, several mechanisms have been sug-
gested, including intramedullary destruction of red blood
cell (RBC) precursors by RBC antibodies, bone marrow
suppression from IUTs, and erythropoietin production that
is inappropriately low for the degree of anemia [1e4]. The
perinatal effects of maternal Rh alloimmunization are now
referred to as hemolytic disease of the fetus and newborn
(Rh-HDN), and these effects are considered the most
common cause of severe hemolytic disease of the newborn.
Prevention can be achieved by administering anti-D
immunoglobulin G prophylaxis soon after delivery to pre-
vent sensitization in Rh-negative women. Intrauterine
transfusion is a method that is used to treat anemia in the
fetus and results in decreases in mortality and the occur-
rence of fetal hydrops.
Hyporegenerative anemia is a well-known complication
of Rh-HDN with an incidence that ranges from 71 to 83%.
This condition typically presents at 1e3 weeks of age and
can last up to 3 months [5e7]. Hyporegenerative anemia
usually resolves spontaneously but causes significant
morbidity due to the prolonged need for RBC transfusions.
In addition to the use of phototherapy and exchange or
top-up transfusion therapies for jaundiced neonates, IVIg
has been shown to decrease the rate of exchange trans-
fusions in severely affected infants [8e11]. In contrast, a
randomized, double-blind, placebo-controlled trial that
included 92 newborn found no difference in the rate of
exchange transfusions between an IVIg group and a placebo
group [12]. Additionally, there were no significant differ-
ences between the groups with respect to the need for
exchange transfusions, phototherapy time, peak bilirubin,
or length of hospital stay.
Erythropoietin has been tried as a treatment for late
hyporegenerative anemia, and the results have been
promising. Reports have shown that recombinant human
erythropoietin (rHuEPO) is effective in treating or pre-
venting late hyporegenerative anemia (Refs. [13,14]).
In this retrospective cohort study, we aimed to deter-
mine the effects of intravenous immunoglobulin (IVIg) on
the course of late hyporegenerative anemia and the re-
quirements for exchange transfusions, days of photo-
therapy and top-up RBC transfusions secondary to Rh-
HDN.2. Patients and methods
All infants admitted to the NICU with Rh-HDN from January
2005 to December 2010 were identified using the NICU
logbook and the NICU database. Rhesus HDN was defined by
a maternal antibody-dependent cell-mediated cytotoxicity
assay result exceeding 50% and a validated functional test
predicting severe hemolysis comparable to an indirect
antiglobulin titer of >1:64 [15]. Late anemia was defined as
a hemoglobin level below the threshold requiring a top-up
transfusion during the first three months of life. Top-up
transfusions were given to anemic infants during their
early hospital course due to hemolysis, and top-up trans-
fusions were given to infants who developed late hypo-
regenerative anemia during the follow up.
The relevant neonatal and maternal data that were
collected from the medical records of the infants and their
mothers included the following: maternal age, affected
previous children, intrauterine blood transfusion, infant
demographic data (i.e., age, birth weight, sex and Apgar
score), hemoglobin levels during the hospital course, bili-
rubin levels, use of phototherapy, top-up and exchange
transfusions, age at the diagnosis of late hyporegenerative
anemia and the resolved and number of top-up trans-
fusions. All infants were followed up as outpatients for a
period of 2e3 months. During the follow up, complete
blood counts were performed for all infants every two
weeks to diagnose late hyporegenerative anemia. The in-
fants were classified into two groups as follows: group 1 was
composed of infants who received IVIg, and group 2 was
composed of infants who did not receive IVIg. Infants with
major congenital anomalies were excluded from this study.
3. Statistical methods
In this study, all statistical analyses were performed with
the software package SAS version 9.3 (Statistical Analysis
System, SAS Institute Inc., Cary, NC, USA). Descriptive
statistics for the continuous variables are reported as the
means  the standard deviations, and categorical variables
are summarized as the frequencies and percentages. The
continuous variables for the two groups of patients were
compared with Student’s independent t-tests, and the
categorical variables were compared with chi-square tests
and Fisher’s exact tests. The statistical level of significance
was set at p < 0.05.
Table 2 Baseline characteristics of the included infants
and their outcomes for the IVIg and no-IVIg groups.
Characteristics IVIg group
(n Z 42)
No-IVIg
group
(n Z 24)
P
Value
GA (weeks) 35.9  2.6 36  2 0.8721
BW (grams) 2526  661 2631  439 0.4348
Apgar score at 1st
minute
6.4  2.4 6.9  1.9 0.3318
Apgar score at 5th
minute
7.9  1.8 8.6  1.3 0.0817
Hemoglobin
immediately
after birth
114.7  41.6 130  46 0.1476
Reticulocyte count 0.9410
 1.0571
0.5933
 0.6140
0.6048
Bilirubin
immediately
after birth
102  41.3 72  32.7 0.0035*
Highest bilirubin 263.9  90.4 208  100 0.0225*
No of top-up
transfusions
1.3  0.5 1.3  0.5 0.8740
No of exchange
transfusions
1.4  0.5 1.8  1.3 0.4913
Phototherapy (days) 3.9  2.1 3.4  1.9 0.2373
Hemoglobin when
Late anemia (LA)
diagnosed
75.3  11 77  25 0.7293
Age (days) when
LA diagnosed
34.9  13.9 43.2  19.8 0.0665
Age (days) when
LA persisted
46.5  13.9 65.5  2 0.1098
Infants received 3
top-up
transfusions
or more for LA
6 2 0.2776
No of top-up
transfusions
for LA
1.8  1.0 1.8  0.7 0.8472
All numerical variables are expressed as the means  the SDs,
and the categorical variables are expressed as the numbers of
infants. LAZ late anemia, *P < 0.05 was considered significant.
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Sixty-six infants with Rh-HDN were enrolled in this study.
Forty-two infants (IVIg group; 22 males) received IVIg at
0.5e1 g/kg, which was administered over 4 h and repeated
every 12 h as necessary. The other 24 infants (no-IVIg
group; 13 males) did not receive IVIg and served as a control
for the IVIg group. As shown in Tables 1 and 2, there were
no significant differences between the two groups in
maternal age, number of previous children affected with
Rh-HDN, intrauterine transfusions, GA, BW, Apgar scores at
the 1st or 5th minutes, hemoglobin immediately after birth
(114.7  41.6 vs. 130  46, PZ 0.1476), reticulocyte count
(0.9410  1.0571 vs. 0.5933  0.6140, PZ 0.6048), number
of top-up transfusions (1.3  0.5 vs.1.3  0.5, PZ 0.8740),
number of exchange transfusions (1.4  0.5 vs.1.8  1.3,
PZ 0.4913), days on phototherapy (3.9  2.1 vs. 3.4  1.9,
P Z 0.2373), hemoglobin level at the first diagnosis of late
anemia (75.3  11vs. 77  25, PZ 0.7293), age (in days) at
the diagnosis of late anemia (34.9  13.9 vs. 43.2  19.8,
P Z 0.0665), age (in days) at the resolution of late anemia
(46.5  13.9 vs. 65.5  2, P Z 0.1098), or the number of
top-up transfusions for late hyporegenerative anemia
(1.8  1.0 vs. 1.8  0.7, P Z 0.8472). The serum bilirubin
immediately after birth and the peak serum bilirubin during
the hospital course were significantly higher in the IVIg
group (P Z 0.0035 and P Z 0.0225) respectively. Although
there were no statistically significant differences, the late
anemia in the IVIg group exhibited a trend toward being
diagnosed and resolved earlier than in the no-IVIg group.
Additionally, a greater proportion of the IVIg group required
3 or more top-up transfusions (n Z 6) compared to the no-
IVIg group (n Z 2), but this difference was not statistically
significant (P Z 0.2776).
5. Discussion
In this retrospective chart review of two cohorts of new-
borns with Rh-HDN who were treated with or without IVIg,
we found that late hyporegenerative anemia in the IVIg
group was diagnosed and resolved earlier compared to the
no-IVIg group. Additionally, a greater proportion of the IVIg
group required three or more top-up transfusions (n Z 6)
compared to the no-IVIg group (n Z 2), but this difference
was not statistically significant. This latter result might
have been mediated by the down regulating effect of IVIg
on erythropoietin. One study showed that IVIg increases the
production of proinflammatory cytokines, which in turn
reduces erythropoietin production [16]. Another studyTable 1 Relevant data from the maternal charts.
Characteristics IVIg group
(n Z 42)
No-IVIg group
(n Z 24)
P Value
Maternal age (y) 35  5.5 34  6.3 0.5254
Affected previous
children
2.4  1.2 2.6  1.3 0.7558
Intrauterine
transfusions
2.3  2.3 3.1  2.7 0.1696
All numerical variables are expressed as the means  the SDs.showed that neonates with anti-glycophorin C hemolytic
disease of fetuses and newborns are unresponsive to
erythropoietin and that this lack of responsiveness can
explained by the antibody inhibiting a protein kinase
through which this hematopoietic growth factor achieves
its effects [17].
Moreover, our study showed that the serum bilirubin
levels immediately after birth and the peak serum bilirubin
levels during the hospital course were higher in the IVIg
group; these findings indicate that the disease was severe in
the IVIg group, which necessitated the use of IVIg was used.
The study also showed that the numbers of exchange trans-
fusions and days on phototherapy did not statistically differ
between the two groups. These findings are in accordance
with the results of several studies. In a randomized double-
blind trial, Santos MC et al. [12] found no difference in the
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cebo groups (6 of 46 (13%) in the IVIg group versus 7 of 46
(15.2%) in theplacebo group (pZ 0.765)). Additionally, there
were no significant differences between these groups with
respect to their need for exchange transfusion, photo-
therapy time, peak bilirubin, or length of hospital stay. In
another randomized, double-blind, placebo-controlled trial
of neonates with rhesus hemolytic disease, Smits-Wintjens
and colleagues [18] found no differences in the frequencies
of exchange transfusions between IVIg andplacebogroups, in
the number of exchange transfusions per patient, or in the
duration of phototherapy. In contrast, Elalfy and colleagues
[19] studied 90 full-term neonates with Rh incompatibility
whowere randomly assigned into one of three groups: group I
was treated with conventional methods; and groups IIa and
IIb received IVIg once at 12 h postnatally if phototherapy was
indicated in doses of 0.5 and 1 g/kg, respectively. These
authors found that IVIg administration at 12hwaseffective in
the treatment of severe Rh-HDN. The low-dose of IVIg (0.5 g/
kg) was found to be as effective as the high-dose (1 g/kg) in
reducing the duration of phototherapy and the hospital stay
but was effective in avoiding exchange transfusion. In a
systematic review of six randomized and quasi-randomized
controlled trials that compared HDIVIG and phototherapy
with phototherapy alone in neonates with Rh and/or ABO
incompatibility, the authors found that significantly fewer
infants required exchange transfusions in the HDIVIG group.
Additionally, these authors found that the hospital stay and
duration of phototherapy were significantly reduced [9].
Moreover, Girish and colleagues [20] compared the effects of
two dose regimes of IVIg (0.5 g/kg vs. 1 g/kg given soon after
birth) on the duration of phototherapy in Rh-isoimmunized
neonates at 32 week gestation and found that the two re-
gimes produced comparable effect on the duration of pho-
totherapy, the duration of the hospital stay and the
requirements for exchange transfusions.
A Cochrane review (Ref. [21]) in 2002 that included 189
term and preterm infants and infants with rhesus and ABO
incompatibility concluded that the use of exchange trans-
fusion was significantly decreased in the immunoglobulin-
treated group and that the mean number of exchange
transfusions per infant was also significantly lower in the
immunoglobulin-treated group. Although the results
revealed a significant reduction in the need for exchange
transfusion in those who were treated with intravenous
immunoglobulin, the authors stated that the applicability
of the results is limited; these authors suggested that re-
sults from additional trials of higher quality should be
awaited. In 2004, The American Academy of Pediatrics
(AAP) recommended the use of IVIg (0.5e1.0 g/kg) for
rhesus HDN in cases in which phototherapy failed on the
basis of the same limited data [22].
A systematic review of randomized and quasi-
randomized controlled trials comparing high-dose intrave-
nous immunoglobulin and phototherapy to phototherapy
alone in infants with HDN due to Rh and/or ABO in-
compatibility has been reported. Six randomized trials
were identified, but only four were included in the review
(a total of 226 infants). Three studies reported the numbers
of exchange transfusions and the fourth exchange and red
cell transfusions together. Meta-analysis of the results of
the four trials revealed a significant reduction in the needfor exchange transfusions (relative risk (RR) 0.28, 95%
confidence intervals (CI) 0.17e0.47). The number needed
to treat was 2.7 [9]. One recent systematic review evalu-
ated the efficacy and safety of IVIg in neonates with iso-
immune hemolytic disease. Twelve studies, including 10
trials (n Z 463) of Rh isoimmunization and five trials
(n Z 350) of ABO isoimmunization (three studies included
both populations), were included. The studies with high
risks of bias showed that IVIg reduced the rate of ET in Rh
isoimmunization, whereas the studies with low risks of bias
that used prophylactic phototherapy did not show a sta-
tistically significant difference. In contrast, the meta-
analysis of the studies with high risks of bias in neonates
with ABO isoimmunization revealed the efficacy of IVIg in
reducing exchange transfusions [23]. The limitations of our
study are primarily the small sample size and the use of
medical charts as the source of information.
6. Conclusion
Although there were no statistically significant differences
between the two groups, there were trends that indicated
that IVIg might have exerted effects on the early develop-
ment of late anemia and shortened the duration of late
anemia relative to the infants who did not receive IVIg. The
numbers of exchange transfusions and the days on photo-
therapy were not affected by IVIg. To avoid these limita-
tions, confirm the results and uncover more or less
favorable results, we recommend that a large prospective
cohort study that includes other local institutions that
manage infants with HDN due to Rh and/or ABO in-
compatibility should be conducted.Conflict of Interest
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